Elanco Animal Health Incorporated ( NYSE : ELAN ) Receives Consensus Recommendation of Moderate Buy from Analysts.

This rating reflects the overall sentiment of the analysts who follow the company. The consensus price target for Elanco is $100.00, which is a significant increase from the stock’s current price of $75.00. This suggests that analysts expect the stock to appreciate significantly in the coming months and years.

Elanco Animal Health, a global leader in animal health, saw its stock price decline by 0.3 percent on Friday, despite strong earnings and a positive outlook. The company’s stock closed at $14.44. **Key Takeaways:**

* **Strong Earnings and Positive Outlook:** Elanco Animal Health posted impressive earnings, exceeding analysts’ expectations and demonstrating robust growth in its core business.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The firm had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period last year, the firm posted $0.18 earnings per share. As a group, equities research analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

This action, while seemingly small to some, signifies a strong confidence in the company’s future and a vote of confidence in Elanco’s leadership. **Further analysis of the insider activity suggests that CEO Jeffrey N. Simmons has been actively engaged in increasing his stake in Elanco Animal Health.** This trend of consistent buying has been observed for several months.

is a large institutional investor with over $100 billion in assets under management. This significant increase in stake suggests a positive outlook on Elanco’s future prospects. On the other hand, another large investor, BlackRock Inc., reduced its stake in Elanco by 12.5% in the fourth quarter.

The company’s mission is to improve animal health and well-being through innovative solutions. Elanco’s history dates back to 1954, when it was founded as a subsidiary of Eli Lilly and Company. Elanco has a global presence, with operations in over 100 countries. The company’s portfolio includes a wide range of products, from vaccines and antibiotics to nutritional supplements and animal health services.

Featured Articles Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.